1. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up 
Diane M. Harper, Pekka Nieminen, Gilbert Donders, Mark H. Einstein, Francisco Garcia, Warner K. Huh, Mark H. Stoler, Katerina Glavini, Gemma Attley, Jean-Marc Limacher, Berangere Bastien, Elizabeth Calleja 
Gynecologic Oncology 
DOI: /j.ygyno
Copyright © 2019 The Authors Terms and Conditions

2. Fig. 1
Trial schematic—700 Patients Screened and subsequent enrollment in the safety population and the modified intent to treat (mITT) population.
Gynecologic Oncology DOI: ( /j.ygyno )
Copyright © 2019 The Authors Terms and Conditions

3. Fig. 2
Viral DNA clearance by Roche Linear Array Assay Fig. 2A. Among baseline CIN 2/3 regardless of HR HPV types through month 30, mITT. Fig. 2B. Among baseline CIN 3 regardless of HR HPV types through month 30, mITT. Fig. C. Among baseline CIN 2/3 by HR HPV type through month 30, mITT.
Gynecologic Oncology DOI: ( /j.ygyno )
Copyright © 2019 The Authors Terms and Conditions